A febre em um paciente com neutropenia pode ser causada por uma infecção bacteriana, viral ou fúngica. Destas, as infecções bacterianas da corrente sanguínea são a etiologia infecciosa mais comumente identificada em pacientes com câncer e neutropenia febril e podem resultar em mortalidade significativa.[19]Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009 Sep;31(9):623-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743072
http://www.ncbi.nlm.nih.gov/pubmed/19644403?tool=bestpractice.com
[20]Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016 Sep;27(5 suppl):v111-8.
https://www.annalsofoncology.org/article/S0923-7534(19)31643-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/27664247?tool=bestpractice.com
[21]Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S51-9.
https://www.sciencedirect.com/science/article/abs/pii/S0924857907002853?via%3Dihub
http://www.ncbi.nlm.nih.gov/pubmed/17689933?tool=bestpractice.com
[22]Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S30-3.
https://www.sciencedirect.com/science/article/abs/pii/S092485790800294X?via%3Dihub
http://www.ncbi.nlm.nih.gov/pubmed/18778919?tool=bestpractice.com
[23]El Assaad N, Azzi A, Haddad F, et al. Febrile neutropenia in the Middle East and North Africa Region: trends, management, and outcomes (2000-2024) - a systematic review. IJID Reg. 2025 Sep;16:100682.
https://www.sciencedirect.com/science/article/pii/S2772707625001171?via%3Dihub
http://www.ncbi.nlm.nih.gov/pubmed/40703205?tool=bestpractice.com
[24]Chumbita M, Peyrony O, Teijón-Lumbreras C, et al. Current microbiological testing approaches and documented infections at febrile neutropenia onset in patients with hematologic malignancies. Int J Infect Dis. 2024 Oct;147:107183.
https://www.ijidonline.com/article/S1201-9712(24)00254-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/39084344?tool=bestpractice.com
A flora endógena do hospedeiro normalmente é a fonte primária de patógenos causadores.[23]El Assaad N, Azzi A, Haddad F, et al. Febrile neutropenia in the Middle East and North Africa Region: trends, management, and outcomes (2000-2024) - a systematic review. IJID Reg. 2025 Sep;16:100682.
https://www.sciencedirect.com/science/article/pii/S2772707625001171?via%3Dihub
http://www.ncbi.nlm.nih.gov/pubmed/40703205?tool=bestpractice.com
[25]Cooksley T, Holland M. The febrile patient with neutropenia. Acute Med. 2012;11(4):246-50.
http://www.ncbi.nlm.nih.gov/pubmed/23364111?tool=bestpractice.com
[26]Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005 Mar 15;103(6):1103-13.
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.20890
http://www.ncbi.nlm.nih.gov/pubmed/15666328?tool=bestpractice.com
[27]Murono K, Hirano Y, Koyano S, et al. Molecular comparison of bacterial isolates from blood with strains colonizing pharynx and intestine in immunocompromised patients with sepsis. J Med Microbiol. 2003 Jun;52(pt 6):527-30.
http://www.ncbi.nlm.nih.gov/pubmed/12748274?tool=bestpractice.com
Dados contemporâneos indicam que organismos Gram-negativos podem ser isolados com mais frequência do que organismos Gram-positivos, provavelmente devido ao aumento da resistência a antibióticos.[28]Erdem H, Kocoglu E, Ankarali H, et al. Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID-IRI study. Int J Antimicrob Agents. 2023 Sep;62(3):106919.
http://www.ncbi.nlm.nih.gov/pubmed/37423582?tool=bestpractice.com
Os organismos Gram-negativos mais comuns incluem Escherichia coli, espécies de Klebsiella e Pseudomonas aeruginosa. Os organismos Gram-positivos mais comuns incluem estafilococos coagulase-negativos, Staphylococcus aureus e espécies de Enterococcus.[28]Erdem H, Kocoglu E, Ankarali H, et al. Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID-IRI study. Int J Antimicrob Agents. 2023 Sep;62(3):106919.
http://www.ncbi.nlm.nih.gov/pubmed/37423582?tool=bestpractice.com
Com o advento de técnicas moleculares avançadas para identificação microbiana, é previsto que haverá um aumento no relato de infecções por anaeróbios na corrente sanguínea microbiologicamente definidas.[29]Gajdács M, Urbán E. Relevance of anaerobic bacteremia in adult patients: a never-ending story? Eur J Microbiol Immunol (Bp). 2020 Jun 5;10(2):64-75.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7391379
http://www.ncbi.nlm.nih.gov/pubmed/32590337?tool=bestpractice.com
Os patógenos virais isolados de pacientes com neutropenia febril incluem vírus respiratórios, o vírus Epstein-Barr e o herpes-vírus humano tipo 6.[24]Chumbita M, Peyrony O, Teijón-Lumbreras C, et al. Current microbiological testing approaches and documented infections at febrile neutropenia onset in patients with hematologic malignancies. Int J Infect Dis. 2024 Oct;147:107183.
https://www.ijidonline.com/article/S1201-9712(24)00254-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/39084344?tool=bestpractice.com
[30]Obrová K, Grumaz S, Remely M, et al. Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. Am J Hematol. 2021 Jun 1;96(6):719-26.
https://onlinelibrary.wiley.com/doi/10.1002/ajh.26177
http://www.ncbi.nlm.nih.gov/pubmed/33784434?tool=bestpractice.com
Fungos (predominantemente espécies de Candida e Aspergillus) são encontrados em 2% a 10% dos pacientes em risco, particularmente naqueles com uso concomitante de corticosteroides, idosos e com neoplasia hematológica recidivada ou refratária.[3]Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):e56-93.
https://academic.oup.com/cid/article/52/4/e56/382256
http://www.ncbi.nlm.nih.gov/pubmed/21258094?tool=bestpractice.com
[31]Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003 May 1;36(9):1103-10.
https://academic.oup.com/cid/article/36/9/1103/311433
http://www.ncbi.nlm.nih.gov/pubmed/12715303?tool=bestpractice.com
É importante observar que o uso de profilaxia antifúngica durante o período neutropênico em determinadas populações de alto risco teve um impacto significativo na redução do risco de infecção fúngica.[32]Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007 Dec 1;25(34):5471-89.
http://www.ncbi.nlm.nih.gov/pubmed/17909198?tool=bestpractice.com